In addition to weight loss, both semaglutide and topiramate have been shown to reduce the risk of obesity-related health problems, like heart disease, high blood pressure, and diabetes
In addition, preclinical evidence on GLP-1 effects in directly modulating the hypothalamuspituitarygonadal (HPG) axis, or the effects of GLP-1RA on clinical and biochemical expression of hyperandrogenism, concern new aspects in PCOS which are probably not always related to weight loss
Finding the right person was difficult because many at the time, like Fraser, were highly sceptical about the clinical potential of RIA
The most common side effects are nausea, diarrhea, constipation, and vomiting primarily during dose escalation and are typically mild to moderate and transient